Yahoo Finance

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...
Benzinga.com

SAB Biotherapeutics And 1 Other Stock Under $1 Insiders Are Aggressively Buying

The Nasdaq 100 gained by more than 100 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or ...
Nasdaq

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG) SAB-142 directly and specifically targets multiple immune ...
Nasdaq

SAB BIO Reports Q1 2025 Financial Results and Progress on SAB-142 for Type 1 Diabetes Treatment

SAB BIO, a clinical-stage biopharmaceutical company focused on developing immunotherapy for type 1 diabetes (T1D), announced its financial results for Q1 2025, highlighting substantial progress in its ...